JCN Newswire Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022 Tagged in : alzheimer's data eisai from study
ACN Newswire TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally Tagged in : contact coordinators patient recruitment study
ACN Newswire Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine Tagged in : clinical dorzagliatin nature study with
JCN Newswire Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway Tagged in : alzheimer's disease lecanemab study with
JCN Newswire Joint Feasibility Study on the Commercialization of Sustainable Aviation Fuel Tagged in : aviation chain international study with
JCN Newswire Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting Tagged in : carriers core lecanemab study with
JCN Newswire Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab Tagged in : clinical eisai lecanemab potential study
ACN Newswire SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE Tagged in : clinical development multiple phase study
JCN Newswire Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study Tagged in : alzheimer's clinical disease nexgen study
JCN Newswire Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium Tagged in : combination merck patients study with
JCN Newswire Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation Tagged in : clinical early phase study with
JCN Newswire Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference Tagged in : alzheimer's clinical efficacy lecanemab study
JCN Newswire Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference Tagged in : amyloid brain clinical elevated study
JCN Newswire Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease Tagged in : alzheimer's clinical disease inherited study
ACN Newswire Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin Tagged in : diabetes dream patients study type
ACN Newswire SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases Tagged in : clinical everest phase study with
JCN Newswire Toyota: Feasibility Study on the Receiving and Distribution Business of Imported Hydrogen in Chubu Regio Tagged in : chubu group hydrogen study utilization
JCN Newswire Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) Tagged in : core lecanemab study treatment with
JCN Newswire Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021 Tagged in : ad-us alzheimer's disease study with
JCN Newswire Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021 Tagged in : alzheimer's clinical disease study will
JCN Newswire Mitsubishi Motors (Thailand) Signs MoU with Eternity Grand Logistics to Do a Pilot Study on Commercial Usage of Compact EVs Tagged in : eternity mitsubishi motors study will
